What Happened?

Shares of financial advisory firm Lazard (NYSE: LAZ) jumped 2.3% in the morning session after the company announced the appointment of Dr. Geoffrey Porges as a Managing Director in its Healthcare Advisory Group. 

Dr. Porges brought over 30 years of experience in the biopharmaceutical industry, having previously served as the Chief Financial Officer at Schrödinger. Lazard’s leadership stated that his deep understanding of the industry’s strategic landscape would help clients capitalize on growth opportunities. The appointment was seen as a move to strengthen the firm's competitive position in a key sector. This news landed in a receptive market, as broader investor sentiment was lifted after the Federal Reserve announced its first interest rate cut of the year, pushing Wall Street to open at higher levels.

After the initial pop the shares cooled down to $57.15, up 2.7% from previous close.

Is now the time to buy Lazard? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Lazard’s shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

Lazard is up 12.6% since the beginning of the year, and at $57.15 per share, it is trading close to its 52-week high of $61.01 from November 2024. Investors who bought $1,000 worth of Lazard’s shares 5 years ago would now be looking at an investment worth $1,651.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.